Previous 10 | Next 10 |
2023-11-03 12:59:13 ET More on BioCryst, Clearside Biomedical, etc. BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2023 Earnings Call Transcript BioCryst Pharmaceuticals: Q3 Earnings May Not Halt This Stock's Bear Run Clearside Biomedical, Inc. (CLSD) Q2 2023 Earnings Call...
Company builds on deep structure-based drug design capabilities to add protein therapeutics to pipeline: BCX17725 for Netherton syndrome — entering clinic in 2H 2024 Bifunctional fusion protein enabling simultaneous inhibition of multiple complement pathways...
– SCS Microinjector is the first and only FDA-approved approach to access the suprachoroidal space – – BioCryst to host R&D Day today at 1:00 pm ET – ALPHARETTA, Ga. and RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2023 (GLOBE NEWSWIRE) -- ...
2023-11-03 05:31:43 ET Image source: The Motley Fool. BioCryst Pharmaceuticals (NASDAQ: BCRX) Q3 2023 Earnings Call Nov 02, 2023 , 8:30 a.m. ET Operator Continue reading For further details see: BioCryst Pharmaceuticals (BCRX) Q3 2023 Earnings...
2023-11-02 16:05:06 ET BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2023 Earnings Conference Call November 2, 2023 08:30 ET Company Participants John Bluth - Investor Relations Jon Stonehouse - Chief Executive Officer Charlie Gayer - Chief Commercial Officer Jink...
2023-11-02 07:13:02 ET More on BioCryst Pharmaceuticals BioCryst Pharmaceuticals: Q3 Earnings May Not Halt This Stock's Bear Run Analyzing BioCryst's Orladeyo Q2 Growth Amidst Competition And Liquidity Hurdles BioCryst Pharmaceuticals Q3 2023 Earnings Preview ...
- Q3 2023 ORLADEYO net revenue of $85.7 million (+29.8 percent y-o-y) -- - Company expects to achieve no less than $320 million in full year 2023 ORLADEYO revenue and $1 billion in peak ORLADEYO revenue - - Net cash utilization of $16.5 million in Q3 2023 (-43.9 percent ...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
BioCryst Pharmaceuticals Inc. (BCRX) is expected to report $-0.25 for Q3 2023
2023-11-01 13:08:27 ET More on BioCryst Pharmaceuticals BioCryst Pharmaceuticals: Q3 Earnings May Not Halt This Stock's Bear Run BioCryst upgraded to buy at Jefferies on undervaluation Seeking Alpha's Quant Rating on BioCryst Pharmaceuticals Historical earnin...
News, Short Squeeze, Breakout and More Instantly...
BioCryst Pharmaceuticals Inc. Company Name:
BCRX Stock Symbol:
NASDAQ Market:
BioCryst Pharmaceuticals Inc. Website:
RESEARCH TRIANGLE PARK, N.C., July 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2024 financial results on Monday, August 5, 2024. BioCryst management will host a conference call and webcast ...
RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has granted approval for oral, once-daily ORLADEYO ® (berotralstat) for t...
2024-06-27 04:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...